Literature DB >> 9312134

The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing.

W Heinemeyer1, M Fischer, T Krimmer, U Stachon, D H Wolf.   

Abstract

The 26 S proteasome is the central protease involved in ubiquitin-mediated protein degradation and fulfills vital regulatory functions in eukaryotes. The proteolytic core of the complex is the 20 S proteasome, a cylindrical particle with two outer rings each made of 7 different alpha-type subunits and two inner rings made of 7 different beta-type subunits. In the archaebacterial 20 S proteasome ancestor proteolytically active sites reside in the 14 uniform beta-subunits. Their N-terminal threonine residues, released by precursor processing, perform the nucleophilic attack for peptide bond hydrolysis. By directed mutational analysis of 20 S proteasomal beta-type proteins of Saccharomyces cerevisiae, we identified three active site-carrying subunits responsible for different peptidolytic activities as follows: Pre3 for post-glutamyl hydrolyzing, Pup1 for trypsin-like, and Pre2 for chymotrypsin-like activity. Double mutants harboring only trypsin-like or chymotrypsin-like activity were viable. Mutation of two potentially active site threonine residues in the Pre4 subunit excluded its catalytic involvement in any of the three peptidase activities. The generation of different, incompletely processed forms of the Pre4 precursor in active site mutants suggested that maturation of non-active proteasomal beta-type subunits is exerted by active subunits and occurs in the fully assembled particle. This trans-acting proteolytic activity might also account for processing intermediates of the active site mutated Pre2 subunit, which was unable to undergo autocatalytic maturation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9312134     DOI: 10.1074/jbc.272.40.25200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  158 in total

Review 1.  The proteasome: a macromolecular assembly designed for controlled proteolysis.

Authors:  P Zwickl; D Voges; W Baumeister
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-09-29       Impact factor: 6.237

2.  The selective proteasome inhibitors lactacystin and epoxomicin can be used to either up- or down-regulate antigen presentation at nontoxic doses.

Authors:  K Schwarz; R de Giuli; G Schmidtke; S Kostka; M van den Broek; K B Kim; C M Crews; R Kraft; M Groettrup
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

3.  Letter to the editor. Chemical-genetic strategy for inhibiting proteasome function in Saccharomyces cerevisiae.

Authors:  Gregory C Howard; Galen A Collins; William P Tansey
Journal:  Yeast       Date:  2011-12-08       Impact factor: 3.239

4.  Bioinformatic analysis of functional differences between the immunoproteasome and the constitutive proteasome.

Authors:  Can Kesmir; Vera van Noort; Rob J de Boer; Paulien Hogeweg
Journal:  Immunogenetics       Date:  2003-08-30       Impact factor: 2.846

5.  Rearrangement of the 16S precursor subunits is essential for the formation of the active 20S proteasome.

Authors:  Srinivas Mullapudi; Lee Pullan; Ozlem T Bishop; Hassan Khalil; James K Stoops; Roland Beckmann; Peter M Kloetzel; Elke Krüger; Pawel A Penczek
Journal:  Biophys J       Date:  2004-09-10       Impact factor: 4.033

6.  The origin of proteasome-inhibitor resistant HLA class I peptidomes: a study with HLA-A*68:01.

Authors:  Noel García-Medel; Alejandro Sanz-Bravo; Eilon Barnea; Arie Admon; José A López de Castro
Journal:  Mol Cell Proteomics       Date:  2011-10-03       Impact factor: 5.911

7.  A panel of subunit-selective activity-based proteasome probes.

Authors:  Martijn Verdoes; Lianne I Willems; Wouter A van der Linden; Boudewijn A Duivenvoorden; Gijsbert A van der Marel; Bogdan I Florea; Alexei F Kisselev; Herman S Overkleeft
Journal:  Org Biomol Chem       Date:  2010-05-06       Impact factor: 3.876

Review 8.  Hemopressin and other bioactive peptides from cytosolic proteins: are these non-classical neuropeptides?

Authors:  Julia S Gelman; Lloyd D Fricker
Journal:  AAPS J       Date:  2010-04-10       Impact factor: 4.009

9.  Nature of pharmacophore influences active site specificity of proteasome inhibitors.

Authors:  Michael Screen; Matthew Britton; Sondra L Downey; Martijn Verdoes; Mathias J Voges; Annet E M Blom; Paul P Geurink; Martijn D P Risseeuw; Bogdan I Florea; Wouter A van der Linden; Alexandre A Pletnev; Herman S Overkleeft; Alexei F Kisselev
Journal:  J Biol Chem       Date:  2010-10-11       Impact factor: 5.157

Review 10.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.